This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olivotto, I. Articles by Cecchi, F. Search for Related Content PubMed PubMed Citation Articles by Olivotto, I. Articles by Cecchi, F.

CLINICAL STUDY: PRIMARY MYOCARDIAL DISEASE

Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy

^* Cardiologia S. Luca, Azienda Ospedaliera Careggi, Florence, Italy

Manuscript received February 19, 2002; revised manuscript received July 16, 2002, accepted August 26, 2002.

^* Reprint requests and correspondence: Dr. Iacopo Olivotto, Studio Medico, Via Jacopo Nardi 30, Firenze, 50132, Italy.
iacopo.olivotto{at}virgilio.it

OBJECTIVES: We sought to assess the relationship between maximum left ventricular (LV) wall thickness and outcome in patients with hypertrophic cardiomyopathy (HCM).

BACKGROUND: An association between maximum LV wall thickness and risk of sudden death was suggested in HCM. This finding requires further investigation, given the important implications for risk stratification and treatment.

METHODS: We analyzed the mortality and risk profile of 237 patients (age 41 ± 17 years; 63% male) classified into five groups based on echocardiographic maximum LV thickness.

RESULTS: During follow-up (12 ± 7 years), 36 patients died of cardiovascular causes, including 16 sudden deaths. Maximum LV thickness was not associated with a risk of sudden death (p = 0.37) nor with overall cardiovascular mortality (p = 0.7). With the exception of the small subset with thickness values 15 mm, with a consistently benign clinical course, the distribution of sudden death and overall cardiovascular mortality was not significantly different among the other four classes, ranging from 16 to 19 mm to 30 mm. Among 30 patients with extreme LV thickness (30 mm), only one sudden event occurred among six patients diagnosed at <18 years of age (17%) and none among 24 diagnosed at 18 years of age. The prevalence of nonsustained ventricular tachycardia, syncope, an abnormal blood pressure response to exercise, and atrial fibrillation was similar among the five thickness classes.

CONCLUSIONS: During 12-year follow-up, we observed no association between maximum LV thickness and cardiovascular mortality in a community-based population with HCM. The degree of maximum LV wall thickness should be considered in the context of a multifactorial approach to risk stratification, rather than as an isolated risk factor. Only in those patients diagnosed at a very young age might the presence of extreme LV wall thickness represent, per se, a potential marker of risk of sudden death.

Abbreviations and Acronyms   HCM   hypertrophic cardiomyopathy   HF   heart failure   LV   left ventricular

This article has been cited by other articles:

				G S Soor, A Luk, E Ahn, J R Abraham, A Woo, A Ralph-Edwards, and J Butany Hypertrophic cardiomyopathy: current understanding and treatment objectives J. Clin. Pathol., March 1, 2009; 62(3): 226 - 235. [Abstract] [Full Text] [PDF]

				Z.-Z. Song Left ventricular mass and the outcome of patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 399 - 399. [Full Text] [PDF]

				I. Olivotto, M. S. Maron, F. Cecchi, and B. J. Maron Reply. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 399 - 399. [Full Text] [PDF]

				P Elliott and P Spirito Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice Heart, October 1, 2008; 94(10): 1269 - 1275. [Abstract] [Full Text] [PDF]

				I. Olivotto, M. S. Maron, C. Autore, J. R. Lesser, L. Rega, G. Casolo, M. De Santis, G. Quarta, S. Nistri, F. Cecchi, et al. Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., August 12, 2008; 52(7): 559 - 566. [Abstract] [Full Text] [PDF]

				C. J. McLeod, S. R. Ommen, M. J. Ackerman, P. L. Weivoda, W. K. Shen, J. A. Dearani, H. V. Schaff, A. J. Tajik, and B. J. Gersh Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy Eur. Heart J., November 1, 2007; 28(21): 2583 - 2588. [Abstract] [Full Text] [PDF]

				A. Nasermoaddeli, K. Miura, A. Matsumori, Y. Soyama, Y. Morikawa, A. Kitabatake, Y. Inaba, and H. Nakagawa Prognosis and prognostic factors in patients with hypertrophic cardiomyopathy in Japan: results from a nationwide study Heart, June 1, 2007; 93(6): 711 - 715. [Abstract] [Full Text] [PDF]

				A. W. Nugent, P. E.F. Daubeney, P. Chondros, J. B. Carlin, S. D. Colan, M. Cheung, A. M. Davis, C.W. Chow, R. G. Weintraub, and for the National Australian Childhood Cardiomyopat Clinical Features and Outcomes of Childhood Hypertrophic Cardiomyopathy: Results From a National Population-Based Study Circulation, August 30, 2005; 112(9): 1332 - 1338. [Abstract] [Full Text] [PDF]

				P. A. Kaufmann and P. G. Camici Myocardial Blood Flow Measurement by PET: Technical Aspects and Clinical Applications J. Nucl. Med., January 1, 2005; 46(1): 75 - 88. [Full Text] [PDF]

				F. Cecchi, I. Olivotto, R. Gistri, R. Lorenzoni, G. Chiriatti, and P. G. Camici Coronary Microvascular Dysfunction and Prognosis in Hypertrophic Cardiomyopathy N. Engl. J. Med., September 11, 2003; 349(11): 1027 - 1035. [Abstract] [Full Text] [PDF]